Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial. CD-001, the ...
ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentationAdditionally, two posters on data from the pioneering use of tape stripping for biomarker ...